Baxter acquires biopharmaceutical company SuppreMol from GermanyStaff writer ▼ | March 7, 2015
Baxter International has acquired SuppreMol GmbH for EUR 200 million (approximately $225 million) before working capital and other adjustments.
Acquisition SuppreMol sold for $225 million
The acquisition includes SuppreMol's early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases, focusing on the modulation of Fc receptor signaling pathways, an immune target that could have broad applications in autoimmune disorders.
In addition to the portfolio, Baxter also acquires and will continue to operate SuppreMol's operations in Munich.
SuppreMol's pipeline includes lead candidate SM101, an investigational immunoregulatory treatment that has completed Phase 2a studies in idiopathic thrombocytopenic purpura (ITP, a disorder causing low platelet levels) and systemic lupus erythematosus (SLE, a disorder in which the immune system attacks healthy tissue).
SM101's Phase 2a data, presented during the American College of Rheumatology's 2014 annual meeting, showed a dose response in multiple endpoints among patients with SLE treated with either one of two different doses of SM101 for six months. The pipeline also includes technologies with potential therapeutic applications in other autoimmune diseases as well as IgE-mediated allergic diseases. ■